RxDoctor Payments Data

Nimrit Goraya, MD

Nephrology · Temple, TXNPI 1518168723

Payments from drug & device makers

$1,012in general payments, 2019–2025

Across 15 payments — averaging $67.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$273
  • Amgen$259
  • Mallinckrodt Enterprises LLC$100
  • Mallinckrodt Hospital Products Inc.$100
  • Veloxis Pharmaceuticals, Inc.$92
  • Nxstage Medical, Inc.$85
  • plus $103 from 3 others

What the payments were for

  • Food & beverage$72171%
  • Education$29129%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,012 in reported general payments places this provider in the 40th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$121,316
Medicare patients
326
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin62$74,332
OzempicSemaglutide45$50,228
VeltassaPatiromer Calcium Sorbitex19$17,829
FarxigaDapagliflozin Propanediol12$16,973
Sevelamer Carbonate22$4,890
Clonidine20$3,797
Losartan Potassium198$2,930
Cinacalcet Hcl14$2,548
Carvedilol139$1,768
Tamsulosin Hcl74$1,592
Amlodipine Besylate192$1,293
Torsemide54$1,215
Furosemide152$1,174
Atorvastatin Calcium78$1,146
Allopurinol93$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$50,22845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →